Ownership and insider activity for Moleculin Biotech, Inc. (MBRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.
Price
| Price | $0.74 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.0M | $7.7M | $7.1M | $10.7M | $15.2M | $70.9M | $43.1M | $23.6M | $4.3M | $8.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $56000 | $11000 | $1000 | $45000 | 0 | 0 | 0 | $7000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $5.2M | $8.3M | $8.0M | $13.5M | $17.2M | $72.5M | $45.6M | $26.3M | $5.2M | $9.7M |
| Property, Plant & Equipment | $23128 | $33000 | $463000 | $603000 | $685000 | $445000 | $678000 | $796000 | $583000 | $314000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $11.1M | $11.1M | $11.1M | $11.1M | $11.1M | $11.1M | $11.1M | $11.1M | $11.1M | $11.1M |
| Total Assets | $16.4M | $19.5M | $19.6M | $25.2M | $29.2M | $84.1M | $57.4M | $38.2M | $16.9M | $22.1M |
| Accounts Payable | $399000 | $810000 | $1.2M | $2.2M | $1.1M | $1.4M | $2.1M | $2.5M | $2.0M | $3.5M |
| Short-term Debt | $296000 | 0 | 0 | $103000 | $118000 | $96000 | 0 | 0 | 0 | $137000 |
| Total Current Liabilities | $1.3M | $2.2M | $3.9M | $3.6M | $2.9M | $3.6M | $4.8M | $6.8M | $5.4M | $6.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.4M | $2.4M | $5.3M | $9.7M | $11.3M | $5.1M | $5.2M | $12.1M | $10.9M | $7.1M |
| Retained Earnings | -$4.7M | -$14.5M | -$26.4M | -$39.6M | -$56.9M | -$72.8M | -$101.8M | -$131.6M | -$153.4M | -$206.0M |
| Total Equity | $15.0M | $17.1M | $14.3M | $15.6M | $17.9M | $79.0M | $52.2M | $26.1M | $6.0M | $15.0M |
| Total Debt | $296412 | 0 | 0 | $379000 | $277000 | $159000 | $451000 | $574000 | $478000 | $359000 |
| Net Debt | -$4.7M | -$7.7M | -$7.1M | -$10.4M | -$14.9M | -$70.7M | -$42.7M | -$23.0M | -$3.8M | -$8.5M |
| Working Capital | $3.9M | $6.1M | $4.1M | $9.9M | $14.3M | $68.9M | $40.8M | $19.5M | -$165000 | $2.8M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 0.94 |
Profitability
| Return on Equity | -816.56% |
| Return on Invested Capital | -242.25% |
| Return on Assets | -143.82% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAP · AIMD · APLM · ATHA · BLRX · CTXR · ICU
Explore sector: Healthcare · Biotechnology
More sections of MBRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks